Premium
Adjuvant Treatment with Yupingfeng Formula for Recurrent Respiratory Tract Infections in Children: A Meta‐analysis of Randomized Controlled Trials
Author(s) -
Song Tao,
Hou Xiaoli,
Yu Xiaohui,
Wang Zhen,
Wang Ruiren,
Li Yanling,
Hu Dan,
Wang Xiaohong,
Xiao Zhengzheng,
Sui Yong,
Zhu Chunhong,
Wang Jing
Publication year - 2016
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5628
Subject(s) - medicine , confidence interval , adjuvant , meta analysis , cochrane library , randomized controlled trial , respiratory tract infections , gastroenterology , clinical trial , adjuvant therapy , respiratory system , chemotherapy
This meta‐analysis aimed to evaluate the immunomodulating function of Yupingfeng Formula (YPFF) in children with recurrent respiratory tract infections (RRTIs). The PubMed, EMBASE, Cochrane Library, CNKI and WanFang databases were searched for randomized controlled trials comparing with and without YPFF for RRTIs in children. Twelve trials with 1236 patients were identified. Adjuvant treatment with YPFF significantly increased serum levels of IgA (weighted mean difference [WMD] 0.33 mg/mL; 95% confidence interval [CI] 0.20 to 0.45), IgG (WMD 1.36 mg/mL; 95% CI 1.06 to 1.65), IgM (WMD 0.16 mg/mL; 95% CI 0.02 to 0.31), and CD3 + T‐lymphocytes (WMD 10.16%; 95% CI 4.62 to 15.69) but not CD4 + T‐lymphocytes (WMD 3.16%; 95% CI −0.27 to 6.59) and CD8 + T‐lymphocytes (WMD −0.84%; 95% CI −2.50 to 0.81). YPFF also reduced the frequency of RRTIs (WMD −3.80 times; 95% CI −4.86 to −2.74) and increased total effective rates of symptom improvement (risk ratio: 1.44; 95% CI 1.19 to 1.75). Adjuvant treatment with YPFF could improve total clinical effective rate and decrease the frequency of respiratory tract infections in children with RRTIs. The beneficial effects of YPFF may be correlated to its immunomodulating action. More well‐designed trials with larger sample sizes are needed to evaluate its efficacy and safety. Copyright © 2016 John Wiley & Sons, Ltd.